Practice Contact Information
Huntsman Cancer Institute, University of Utah School of Medicine
50
NORTH MEDICAL DR, SOM 3C-120
SALT LAKE CITY
Utah
84132
United States
Phone:
Email:
Web Site: https://healthcare.utah.edu/find-a-doctor/marcus-m-monroe
Areas of surgical specialization
Endocrine Surgery, Head and Neck Research, Head and Neck Surgeon, Reconstructive Head & Neck Surgery
Biography/Statement
Marcus Monroe, M.D., is an associate professor in the Department of Otolaryngology at the University of Utah School of Medicine. He is a surgeon and investigator with the Huntsman Cancer Institute where he specializes in the complex multidisciplinary care of patients with head and neck cancer. He serves as the Division Chief for Head and Neck Surgical Oncology within the Department of Otolaryngology, as well as the Physician Lead for the Head and Neck Clinical Trials Program and c0-lead for the Head and Neck Disease Center at the Huntsman Cancer Institute.
Dr. Monroe received his medical degree at the University of Missouri—Columbia School of Medicine and completed his residency training in Otolaryngology—Head and Neck Surgery at Oregon Health and Science University (OHSU) in Portland, Oregon. Prior to joining the faculty at the University of Utah, Dr. Monroe completed a fellowship in Head and Neck Surgical Oncology at the University of Texas M.D. Anderson Cancer Center.
His clinical practice involves treating patients with head and neck melanoma and nonmelanoma skin cancers, thyroid and parathyroid tumors, salivary gland tumors, and cancers of the upper aerodigestive tract (oral cavity, pharynx, larynx, and sinuses). Dr. Monroe believes that the best care comes when a team of specialists works together to create a treatment plan that is tailored to the individual patient. Because of this he works closely with a team of multidisciplinary cancer specialists to determine the best possible treatment for each patient.
Dr. Monroe’s research interests are focused on clinical trials for head and neck cancers, risk stratification for advanced skin cancers, and survivorship issues following head and neck cancer treatment.
Clinical Trials
- Phase I Study Of Oral LOXO-292 In Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, And Other Tumors With Increased RET Activity
- Phase III, Randomized, Double-blind, Placebo-Controlled Study To Evaluate Pembrolizumab Versus Placebo As Adjuvant Therapy Following Surgery And Radiation In Participants With High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
- Phase I/IB study of DS-8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial)
- Pembrolizumab in Combination with Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer
- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mb/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti LAG-3) and INCAGN02390 (Anti TIM-3) as First-Line Treatment in Participants With PD-L1 Positive (CPS 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients with Advanced Solid Tumors
- Phase II Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
- Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158(petosemtamab) as single agent or in combination in advanced solid tumors
- DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
- Open-Label, Randomized, Controlled Multicenter Study of the Efficacy of Daromun Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients
- EnergyPoints: A Mobile App Guiding Acupressure Use for Cancer Related Fatigue and Sleep Disturbances
- Phase I/II Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Metastatic Melanoma Who Progressed On Prior BRAF/MEK Inhibitor Therapy
- Phase I/IB study of DS-8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial)
- Pembrolizumab in Combination with Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer
- Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
- RISE-UP (Risk Information and Skin-Cancer Education and Undergraduate Prevention) Trial (R01 version)
- Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study
- A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients with Advanced Solid Tumors
- Phase I Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies
- RADVAX: Randomized Phase II Trial Of Ipilimumab And Nivolumab With Or Without Hypofractionated Radiotherapy In Patients With Metastatic Melanoma
- Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
- Phase I/II, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer